NeuroNova AB

Discovery and development of drugs and therapeutic cells for the treatment of disorders of the central nervous system such as Parkinson’s disease, Alzheimer’s disease, stroke, and spinal cord injury.

NeuroNova AB is an emerging Swedish biopharmaceutical company, founded by Jonas Frisén and Ann Marie Janson from the Karolinska Institute. In autumn 2003, NeuroNova completed a new round of financing totaling 12 €million; the company cooperates with Lundbeck A/S.

Ulf Ljungberg, PhD, President and CEO
Anders Haegerstrand, MD, PhD, VP and CSO
Kerstin M Genetay, Ph.D., Senior Project and Patent Manager
Henrik Resmark, MSc, CFO
Lilian Wikström, PhD, Head of Research
Markus Jerling, M.D., Ph.D., CMO

Carl-Gustaf Johansson, Chairman
Jonas Frisén, M.D., Ph.D.
Karin Hehenberger, M.D., Ph.D.
Staffan Josephson, Ph.D.
Staffan Lindstrand, MSc
Johan Christenson, Ph.D.

Fiskartorpsvägen 15A-D
114 33 Stockholm
Sweden
Phone: +46-8-786-0900
Fax: +46-8-786-0911

The three current programmes of the company are focused on the development of drugs that stimulate endogenous precursor cells (stem or progenitor cells) to repopulate damaged areas of the brain (therapeutic neurogenesis); generating cultured adult precursor cells capable of restoring brain function following transplantation in patients with CNS disorders (cell therapy), and CNS drug discovery technology for investigating the mechanisms underlying neurogenesis.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.